Search all trials

Find therapies in clinical trials near you – page 12

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer

Not yet recruiting

InvestigationalNo placebo

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

InvestigationalNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:1-{6-[(4M)-4-(5-Chloro-6-Methyl-1H -Indazol-4-Yl)-5-Methyl-3-(1-Methyl-1H -Indazol-5-Yl)-1H -Pyrazol-1-Yl]-2-Azaspiro[3.3]Heptan-2-Yl}Prop-2-En-1-One

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Registered drugNo placebo

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Registered drugNo placebo

Finland

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Registered drugNo placebo

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer+4

Not yet recruiting

InvestigationalNo placebo

Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Non-small cell lung cancer+3

Not yet recruiting

InvestigationalNo placebo

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Disitamab Vedotin

Contact Research Centre

Non-small cell lung cancer+1

Not yet recruiting

Registered drugNo placebo

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Cemiplimab

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Registered drugNo placebo

Study of Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Atezolizumab

Contact Research Centre

Non-small cell lung cancer

Not recruiting

InvestigationalNo placebo

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amg 193

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Batoprotafib

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Cobolimab

Contact Research Centre

Find therapies in clinical trials near you – page 12

325 trials match your criteria

Non-small cell lung cancer

Study on JDQ443 for First-Line Treatment in Patients with Advanced KRAS G12C-Mutated Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study on JDQ443 and Docetaxel for Patients with Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Non-small cell lung cancer+4

Study of INCB099280 and Adagrasib for Adults with Advanced Solid Tumors with KRASG12C Mutation

Non-small cell lung cancer+3

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

Non-small cell lung cancer+1

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Non-small cell lung cancer

Study of Tiragolumab, Atezolizumab, and Chemotherapy for Patients with Non-Small Cell Lung Cancer (NSCLC)

Non-small cell lung cancer

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

Non-small cell lung cancer

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Non-small cell lung cancer

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Non-small cell lung cancer

Continuation study of JDQ443 in patients with KRAS G12C‑mutated non‑small cell lung cancer receiving JDQ443 as monotherapy or drug combination

Non-small cell lung cancer

Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.